Evidence map›Paper›PMID 36601547›Full record

ArticleJAC-antimicrobial resistance2023

Real-life temocillin use in Greater Paris area, effectiveness and risk factors for failure in infections caused by ESBL-producing Enterobacterales: a multicentre retrospective study.

Aurélien Dinh, Clara Duran, Simrandeep Singh, Chloé Tesmoingt, Laura Bouabdallah, Antoine Hamon, Marie Antignac, Clément Ourghanlian, Marie-Caroline Loustalot, Jean Baptiste Pain and 5 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Temocillin: A Narrative Review of Its Clinical Reappraisal.Antibiotics (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Comparative Analysis betweenMicroorganisms · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Aurélien DinhInfectious Disease Department, Raymond-Poincaré Hospital, AP-HP, Université Paris Saclay, Garches, France.
Clara DuranInfectious Disease Department, Raymond-Poincaré Hospital, AP-HP, Université Paris Saclay, Garches, France.
Simrandeep SinghPharmacy Department, Cochin Hospital, AP-HP, Centre-Université Paris Cité, Paris, France.
Chloé TesmoingtPharmacy Department, Bichat Hospital, AP-HP, Nord-Université Paris Cité, Paris, France.
Laura BouabdallahPharmacy Department, Saint-Louis Hospital, AP-HP, Nord-Université Paris Cité, Paris, France.
Antoine HamonInternal Medicine Department, Beaujon Hospital, AP-HP, Nord-Université Paris Cité, Clichy, France.
Marie AntignacPharmacy Department, Saint-Antoine Hospital, AP-HP, Sorbonne Université, Paris, France.
Clément OurghanlianPharmacy Department, Henri-Mondor Hospital, AP-HP, HU Henri Mondor, Creteil, France.
Marie-Caroline LoustalotPharmacy Department, Hôpital Européen Georges Pompidou, AP-HP, Centre-Université Paris Cité, Paris, France.
Jean Baptiste PainPharmacy Department, Tenon Hospital, AP-HP, Sorbonne Université, Paris, France.
Benjamin WyploszTropical and Infectious Disease Department, Bicêtre Hospital, AP-HP, Université Paris Saclay, Kremlin-Bicêtre, France.
Helga JunotPharmacy Department, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France.
Alexandre BleibtreuInfectious Disease Department, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France.ORCID https://orcid.org/0000-0001-5145-4174
Hugues MichelonPharmacy Department, Raymond-Poincaré Hospital, AP-HP, Université Paris Saclay, Garches, France.
Temocillin Greater Paris Study Group
Université Paris Cité · FRUniversité Paris-Saclay · FRSorbonne Université · FRAssistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Temocillin is a β-lactam that is not hydrolysed by ESBLs. Objectives: To describe the real-life use of temocillin, to assess its effectiveness in infections caused by ESBL-producing Enterobacterales, and to identify risk factors for treatment failure. Methods: Retrospective multicentric study in eight tertiary care hospitals in the Greater Paris area, including patients who received at least one dose of temocillin for ESBL infections from 1 January to 31 December 2018. Failure was a composite criterion defined within 28 day follow-up by persistence or reappearance of signs of infection, and/or switch to suppressive antibiotic treatment and/or death from infection. A logistic regression with univariable and multivariable analysis was performed to identify risks associated with failure. Results: Data on 130 infection episodes were collected; 113 were due to ESBL-producing Enterobacterales. Mean age was 65.2 ± 15.7 years and 68.1% patients were male. Indications were mostly urinary tract infections (UTIs) (85.8%), bloodstream infections (11.5%), respiratory tract infections (RTIs) (3.5%) and intra-abdominal infections (3.5%). Bacteria involved were Conclusions: The main use of temocillin was UTI due to ESBL-producing

Identifiers

PMID36601547
PMCPMC9798080
OpenAlexW4313477637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.